Creative Biolabs Released High-quality Maytansinoid for Antibody-drug Conjugates Development

Creative Biolabs, a leading provider in antibody-drug conjugate filed, recently released the high-quality maytansinoid, a new payload for ADC development. With years of experience and our advanced “DrugLnk” synthetic chemistry platform, Creative Biolabs has established a comprehensive service program for antibody-drug conjugates (ADCs) developments.

As members of the ansamycins superfamily, maytansine and its derivatives (named as maytansinoids in general) contains 19-member macrocyclic lactams attached to a chlorinated benzene. Originally isolated from an Ethiopian shrub Maytenus ovatus, maytansine exerts extremely high anti-mitotic potency.

“As tubulin inhibitors, maytansinoids and its analogues inhibit the assembly of microtubules by binding to tubulin at or near the vinblastine-binding site. Our professional scientists can help design and provide clients with customized antibody-drug conjugates (ADCs) containing different maytansinoid variants using optimized linkers and suitable conjugation strategies,” said a scientist in Creative Biolabs

“Maytansinoid can decrease microtubule dynamic instability and cause mitotic arrest in cells, similar to the MOA of vinblastine. We can provide several antibody-maytansinoid conjugates as good anti-cancer candidates, such as T-DM1 (trastuzumab-MCC-DM1). It is an ADC in which maytansinoid is conjugated to the anti-HER2 antibody trastuzumab showed superb efficacy against metastatic breast cancer. Meanwhile, lorvotuzumab mertansine (huN901-SPP-DM1), a CD-56 targeting ADC, has also revealed hopeful results in solid and liquid tumors that express CD56.

Based on the comprehensive “DrugLnk” synthesis platforms and extensive experience in ADC preparation, Creative BioLabs can help our clients create unique antibody-maytansinoid conjugates with optimized linkers to meet your specific requirements and provide you with other ADC-related products or services.

About Creative Biolabs

Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, we have established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world.

Media Contact
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States